Abstract: The invention comprises several embodiments of a multi-step method for processing hard tissues, including bone, teeth, tooth enamel and dentin, mollusk shells, crustacean shells, deep sea sponge, coral, radiolarians, diatoms, antler bone, and other naturally occurring mineralized biocomposites, and soft tissues, including connective tissue, cartilage, tendon, ligament, vertebral discs, pathological mineralized soft tissues and other soft tissues, including at least processing a portion of tissue by one or more of contacting, immersing, adding and mixing a portion of tissue with a first solution, obtaining a first material, derived from processing the portion of tissue with the first solution, processing the first material using one or more alkali metal and ammonium salts of citrate, acetate, phosphate, sulfate, tartarate and chloride, and obtaining a resulting material, derived from processing the first material with the one or more salts.

Abstract: The disclosure relates generally to bacterial strains of the genus Christensenella, e.g., Christensenella sp. P152-H6d bacterial strains, and compositions comprising such bacterial strains. The disclosure further relates to methods of using such bacterial strains and compositions for preventing or treating a disorder, e.g., an inflammatory disorder, a gastrointestinal disorder, a metabolic disorder, and/or dysbiosis.

Abstract: The present invention discloses an application of a medical cell CMU-pb-7 in preparation of blood lipid-lowering drugs, which belongs to the technical field of biology. The medical cell CMU-pb-7 disclosed by the present invention is a newly discovered strain of Lactobacillus rhamnosus, having a collection number of CCTCC NO: M 2022220. The medical cell CMU-pb-7 of the present invention can relieve impaired glucose tolerance caused by a high-fat diet in mice with hyperlipidemia, reduce the blood lipid level, enhance the antioxidant capacity of the liver tissue, and regulate the expression of key proteins of liver lipid metabolism to relieve fatty change caused by a high-fat diet. The medical cell CMU-pb-7 disclosed by the present invention has a great potential application prospect in preparation of blood lipid-lowering drugs.

Abstract: The present invention relates to edible plant parts or tissues comprising probiotic bacteria and use thereof for oral delivery of the probiotic bacteria to an organism and enriching and/or improving the organism gastrointestinal tract microbiome. The present invention further relates to methods for selecting and/or producing probiotic bacteria capable of colonizing a plant tissue.

Abstract: The present invention relates to vesicles derived from bacteria of the genus Sphingomonas and a use thereof. These vesicles were significantly decreased in clinical samples of patients with hepatic cirrhosis, liver cancer, myocardial infarction, renal insufficiency, diabetes, brain tumors, mild cognitive impairment, dementia, depression, autism, and atopic dermatitis as compared to normal individuals. Administration of isolated vesicles suppressed secretion of inflammatory mediators by pathogenic vesicles such as E. coli-derived vesicles. Upon oral administration, the vesicles were distributed in the brain tissue. Vesicles derived from bacteria of the genus Sphingomonas are envisioned for use in methods of diagnosis, as well as compositions and methods for treating, hepatic cirrhosis, liver cancer, myocardial infarction, renal insufficiency, diabetes, brain tumors, mild cognitive impairment, dementia, depression, autism, and atopic dermatitis.

Abstract: The present invention provides a therapeutic agent for disc herniation, which has extremely few adverse side effects, can achieve a prolonged pain-ameliorating effect when administered in only a single dose, and can exhibit a high therapeutic effect and high safety in clinical applications. The present invention relates to a therapeutic agent for disc herniation, which is characterized by containing chondroitinase ABC as an active ingredient and being administered in such a manner that the ingredient can be administered into a human disk in an amount of 1-8 units per disk.

Abstract: Methods and compositions diagnose and treat degenerative mitral valve disease in a canine. A method of treating or slowing progression of degenerative mitral valve disease in a canine can include administering a composition to the canine, and the composition contains at least one probiotic that is Butyricicoccus and/or Faecalibacterium The composition can be a pet food or administered in conjunction with a pet food.

Abstract: The invention relates to direct-fed microbials for use in E. coli, Salmonella, and/or Campylobacter inhibition in animals. More particularly, the invention relates to isolated Bacillus strains A12, 54, 681, 101, 235, and 721, and strains having all of the identifying characteristics of these strains, for a use comprising the above-mentioned use. The invention also relates to the use of isolated Bacillus strains 681,721, A12, 54, 86, 300, 101, 102, 235, and 177, and strains having all of the identifying characteristics of these strains, to prevent or reduce prolapse in an animal.

Abstract: A novel method of growing fungi is disclosed which uses an engineered artificial media and produces high density filamentous fungi biomats that can be harvested with a minimum of processing and from which fungal products such as antibiotics, proteins, and lipids can be isolated, the method resulting in lowered fungus cultivation costs for energy usage, oxygenation, water usage and waste stream production.

Abstract: A feed additive composition comprising a direct fed microbial (DFM), in combination with a xylanase (e.g. endo-1,4-?-d-xylanase) and a ?-glucanase (and optionally a further fibre degrading enzyme).

Abstract: Provided is the use of or compositions or formulations comprising Burkholderia species, filtrate, supernatant, extract, pesticidally active compound or metabolite derived therefrom as an insecticide, particularly against infestation of Corn Rootworm larvae, and/or as crop yield enhancer.

Abstract: In an aspect, the present disclosure provides a method for printing an object, comprising: directing at least one energy beam from an energy source into a media chamber comprising at least one polymeric precursor to generate said object at a fine resolution within a certain time period.

Abstract: The present invention relates to the field of microbiology, specifically the field of production of a dairy food product using fermentation and the field of gene transfer by conjugation.

Abstract: A method for determining whether a test sample contains a phytopathogenic fungus selectively from two kinds of fungi of a phytopathogenic fungus and a non-phytopathogenic fungus. The method comprises: (a) putting the test sample on a front surface of a substrate comprising a through hole; wherein the substrate comprises a cellulose film on a back surface thereof; the cellulose film has no through hole; the cellulose film has a thickness of more than 2 micrometers and not more than 3.7 micrometers; and the through hole has a cross-sectional area of not less than 7.065 square micrometers and not more than 19.625 square micrometers; (b) leaving the test sample at rest; (c) observing a back surface of the cellulose film; and (d) determining that the test sample contains the phytopathogenic fungus, if a fungus which has penetrated the cellulose film is found on the back surface of the cellulose film.

Abstract: The present disclosure provides compositions formulated for ruminants that comprise beneficial microbes. Particularly, the disclosure provides a composition comprising microorganisms with at least 97% sequence identity to any one of SEQ ID NOs: 1-60 and 2045-2107. Such compositions can be used for increasing milk production or improving milk compositional characteristics in ruminants.

Abstract: A novel method of growing fungi is disclosed which uses an engineered artificial media and produces high density filamentous fungi biomats that can be harvested with a minimum of processing and from which fungal products such as antibiotics, proteins, and lipids can be isolated, the method resulting in lowered fungus cultivation costs for energy usage, oxygenation, water usage and waste stream production.

Abstract: Provided herein are methods and compositions for treating von Willebrand disease with platelets, platelet derivatives, and/or thrombosomes.

Abstract: The present disclosure provides compositions, enema products, and enema delivery systems used for gastric, gastrointestinal and/or colonic treatments; and methods for making and using them. Methods of the invention are used for the stabilization, amelioration, treatment and/or prevention of constipation, for the treatment of abdominal pain, particularly non-specific abdominal pain, and diarrhea, including diarrhea caused by a drug side effect, a psychological condition, a disease or a condition such as Crohn's Disease, a poison, a toxin or an infection, e.g., a toxin-mediated traveler's diarrhea, or C. difficile or the pseudo-membranous colitis associated with this infection.

Abstract: The present disclosure provides compositions, e.g., formulations, used for gastric, gastrointestinal and/or colonic treatments; and methods for making and using them. Methods of the invention are used for the stabilization, amelioration, treatment and/or prevention of constipation, for the treatment of abdominal pain, particularly non-specific abdominal pain, and diarrhea, including diarrhea caused by a drug side effect, a psychological condition, a disease or a condition such as Crohn's Disease, a poison, a toxin or an infection, e.g., a toxin-mediated traveler's diarrhea, or C. difficile or the pseudo-membranous colitis associated with this infection.

Abstract: A method of inhibiting mycotoxin growth in a site susceptible to mycotoxin contamination, comprising obtaining a Arthrospira platensis, reducing the Arthrospira platensis to nanoparticles, and dispensing the Arthrospira platensis nanoparticles to the site susceptible to mycotoxin growth. In an embodiment, the site vulnerable to mycotoxin contamination is an animal feed supply. In an embodiment, the site susceptible to mycotoxin contamination is wastewater. Use of the Arthrospira platensis nanoparticles efficiently inhibits or prevents mycotoxin contamination.